Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-VV410 in active refractory SLE or LN
NCT07109986Phase 1Recruiting
- Sponsor
- Reindeer Biotech
- Start
- Oct 2025
- Primary completion
- May 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UB-VV400/410 in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Reindeer Biotech. Primary endpoints: Number of participants with adverse events at 24 months and Maximum tolerated dose or maximum administered dose at 24 months. Started Oct 2025; status: recruiting.
02
Drugs
UB-VV400/410
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07109986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109986.